Cellectis SA

CLLS · NYSE

$0.98+$0.005 (+0.51%)TodayMarket closed · Oct 23, 7:30 PM ET

Prev close $0.975

CLLS analyst rating

HoldConsensus of 5 analysts over the last 12 months. 40% rate it a buy.

Strong buy0
Buy2
Hold2
Underperform1
Sell0

12-month price target · 3 analysts

Average $3.18 (+224.2% upside)

Low: $3.15
Now: $0.98
High: $3.27

Upgrades and downgrades

The latest rating actions, newest first

CLLS analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Barclays	Sep 16, 2026	Downgrade	Overweight → Underweight	$9.00 → $1.30	43%
Wells Fargo	Sep 15, 2026	Maintains	Equal-Weight	$4.00 → $3.00	33%
Baird	Sep 15, 2026	Maintains	Outperform	$10.00 → $8.00	33%
Citizens	Sep 15, 2026	Downgrade	Market Outperform → Market Perform	—	21%
Barclays	May 28, 2026	Initiates	Overweight	$9.00	43%
Citizens	Apr 14, 2026	Maintains	Market Outperform	$8.00	21%
Clear Street	Dec 23, 2025	Initiates	Buy	$9.00	13%

The case for and against

Updated Nov 24, 2024

Bull case

Cellectis SA is making significant strides in the biotechnology sector, particularly with its proprietary gene-editing technologies, which position the company favorably within the competitive landscape of immuno-oncology. The company’s robust portfolio of allogeneic UCART product candidates and gene-edited HSPC candidates highlights its commitment to innovative therapeutic solutions, potentially resulting in expansive market opportunities. Furthermore, Cellectis's advancements in clinical trial progress and collaborations with leading industry partners underscore its strong growth prospects, enhancing investor confidence in the company's long-term value.

Bear case

Cellectis SA's reliance on clinical-stage development carries inherent risks, particularly reflected in the delayed timelines for its UCART product candidates, which may hinder potential revenue streams and investor confidence. Additionally, the company’s increasing operational costs and R&D expenditures, without corresponding advancements in monetizable products, contribute to a concerning financial outlook. Furthermore, the competitive landscape in the gene-editing and immuno-oncology sectors poses significant challenges, as Cellectis must navigate scientific and regulatory hurdles to achieve commercial viability.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.